Literature DB >> 23086460

Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.

Farhan Ahmad Pasha1, Mohammad Morshed Neaz.   

Abstract

Abnormal expression of cyclin-dependent kinase 2 (CDK2)/cyclin-E is detected in colorectal, ovarian, breast and prostate cancers. The study of CDK2 with a bound inhibitor revealed CDK2 as a potential therapeutic target for several proliferative diseases. Several highly selective inhibitors of CDK2 are currently undergoing clinical trials, but possibilities remain for the identification and development of novel and improved inhibitors. For example, in silico targeting of ATP-competitive inhibitors of CDKs is of special interest. A series of 3,5-diaminoindazoles was studied using molecular docking and comparative field analyses. We used post-docking short time molecular dynamics (MD) simulation to account for receptor flexibility. The three types of structures, i.e., the highest energy, lowest energy and the structure most resembling the X-ray structure (three complexes) were identified for all ligands. QM/MM energy calculations were performed using a DFT b3lyp/6-31 g* and MM OPLS-2005 force field. Conceptual DFT properties such as the interaction energy of ligand to protein, global hardness (η), HOMO density, electrostatic potential, and electron density were calculated and related to inhibitory activity. CoMFA and CoMSIA were used to account for steric and electrostatic interactions. The results of this study provide insight into the bioactive conformation, interactions involved, and the effect of different drug fragments over different biological activities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086460     DOI: 10.1007/s00894-012-1620-z

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  33 in total

1.  A method for biomolecular structural recognition and docking allowing conformational flexibility.

Authors:  B Sandak; R Nussinov; H J Wolfson
Journal:  J Comput Biol       Date:  1998       Impact factor: 1.479

2.  Kinetic basis for activation of CDK2/cyclin A by phosphorylation.

Authors:  J C Hagopian; M P Kirtley; L M Stevenson; R M Gergis; A A Russo; N P Pavletich; S M Parsons; J Lew
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

3.  DFT-based de novo QSAR of Phenoloxidase Inhibitors.

Authors:  Farhan Ahmad Pasha; Muhhammad Muddassar; Yakub Beg; Seung Joo Cho
Journal:  Chem Biol Drug Des       Date:  2008-05       Impact factor: 2.817

Review 4.  The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.

Authors:  Andrei L Gartel; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

5.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

6.  Inhibition of CDKs as a therapeutic modality.

Authors:  E A Sausville; J Johnson; M Alley; D Zaharevitz; A M Senderowicz
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

7.  Pharmacophore and docking-based combined in-silico study of KDR inhibitors.

Authors:  F A Pasha; M Muddassar; M M Neaz; Seung Joo Cho
Journal:  J Mol Graph Model       Date:  2009-04-19       Impact factor: 2.518

8.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

9.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

Authors:  A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

10.  Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2.

Authors:  D Desai; H C Wessling; R P Fisher; D O Morgan
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

View more
  2 in total

Review 1.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

2.  Inhibition of cyclin-dependent kinase CDK1 by oxindolimine ligands and corresponding copper and zinc complexes.

Authors:  Rodrigo Bernardi Miguel; Philippe Alexandre Divina Petersen; Fernando A Gonzales-Zubiate; Carla Columbano Oliveira; Naresh Kumar; Rafael Rodrigues do Nascimento; Helena Maria Petrilli; Ana Maria da Costa Ferreira
Journal:  J Biol Inorg Chem       Date:  2015-09-28       Impact factor: 3.358

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.